NDAORALTABLET
Approved
Nov 2012
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Data completeness
4/8 — Partial
XELJANZ (tofacitinib) by Pfizer. Approved for rheumatoid arthritis, ulcerative colitis, psoriatic arthritis. First approved in 2012.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XELJANZ (tofacitinib) is an oral Janus Kinase (JAK) inhibitor approved in 2012 for rheumatoid arthritis, ulcerative colitis, and psoriatic arthritis. It works by blocking JAK signaling pathways to reduce inflammatory immune responses. The drug represents a shift from injectable biologics to convenient oral therapy in immunology.
LOE Approaching
Declining
1mo to LOEWith only 0.1 years remaining before LOE, the XELJANZ brand team is in crisis management mode, prioritizing retention programs and preparing for generic erosion; expect reduced headcount and consolidation into a lifecycle management team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (3)
Worked on XELJANZ at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.